Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246857 · ClinicalTrials.gov registry record
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
A clinical trial of Primary Immune Deficiency, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 7
- Study locations
NCT00246857: Recruiting study of Primary Immune Deficiency, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00246857 is a study of Primary Immune Deficiency that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5,000 participants, above the 205-participant average among 5 other Primary Immune Deficiency trials with a reported enrollment target (2339% higher). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246857, a study of Primary Immune Deficiency, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system in the cell growth and cell death processes that regulate lymphocyte homeostasis. Patients who have, or are suspected of having, an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome may be eligible for this study. Relatives of patients are also included. Participants' (patients and relatives) medical records are reviewed and blood samples are drawn for studies to identify genes involved in immune disorders. Tissues that have been removed from patients for medical reasons, such as biopsied tissues, may be examined for tissue and DNA studies. Relatives are studied to determine if some of them may have a very mild form of lymphocyte homeostasis disorder. Patients who have an immune problem that the researchers wish to study further will be invited to donate additional blood samples at irregular intervals (at least once a year) and to provide an update of their medical records at the same time.
Primary Outcome
Goal of this study is to determine the molecular, genetic, biochemical basis for an immune problem.
Conditions Studied
Study Locations (7)
Other
- Ankara Medical University - Ankara
- Gazi University - Ankara
- Hacettepe University - Ankara
- Marmara University - Istanbul
- Necemttin Erbakan University - Konya
Maryland
- National Institutes of Health Clinical Center - Bethesda
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2007-02-12 |
What NCT00246857 shows while recruiting
NCT00246857 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 205-participant average among 5 other Primary Immune Deficiency trials with a reported enrollment target (2339% higher).
The record links to 1 condition, with Primary Immune Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00246857 lists 7 locations in 3 states (Other, Maryland, Michigan).
Frequently Asked Questions
What is clinical trial NCT00246857 about?
NCT00246857 is a clinical study titled "Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death". This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People ...
What is the current status of trial NCT00246857?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2007-02-12.
What conditions does trial NCT00246857 study?
This clinical trial studies the following conditions: Primary Immune Deficiency.
Who is sponsoring clinical trial NCT00246857?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00246857 being conducted?
This trial has 7 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biologics And Clinical Immunology Cohort at Sinai
RECRUITING
-
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
ACTIVE NOT RECRUITING · Phase 3
-
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
ACTIVE NOT RECRUITING · Phase 3
-
COVID-19 Vaccine Responses in PIDD Subjects
ACTIVE NOT RECRUITING
-
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI